A practical reference on lyophilization: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-04. Anything still debated is marked as such rather than presented as settled.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
| Property | Value | Notes |
|---|---|---|
| Primary target | Growth hormone-releasing hormone receptor | Located on anterior pituitary somatotroph cells. |
| Receptor class | G protein-coupled receptor | Activation increases intracellular cyclic AMP. |
| Main downstream hormone | Growth hormone and insulin-like growth factor 1 | Growth hormone release precedes IGF-1 elevation. |
| Primary studied effect | Reduction in visceral adipose tissue | Measured by computed tomography in clinical trials. |
| Approximate half-life | 26–38 minutes after subcutaneous administration | Values vary by assay and study population. |
Lyophilized material is typically held under refrigeration between two and eight degrees Celsius, shielded from light and ambient moisture. Peptides of this size adsorb to glass and plastic, so working procedures often call for low-binding containers and as few transfers as possible. Absorbed water during weighing shifts the apparent mass of a sample, and controlling room humidity reduces that source of error. Once dissolved, solutions are kept cold and used within the interval printed on the accompanying label or certificate. Degradation accelerates markedly in dilute aqueous form.
Identity and purity are judged through a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact peptide from truncated, oxidized, and deamidated variants, and the resulting peak-area percentages yield a purity figure. Electrospray ionization mass spectrometry confirms the expected molecular mass and can expose unanticipated modifications. Amino acid analysis and peptide mapping support sequence fidelity, while water content, pH, sterility, and bacterial endotoxin testing describe the physical and microbiological attributes of a finished lot.
Regulatory position depends on jurisdiction and on the form in which the material is sold. A branded product holds approval in the United States for a defined indication, and prescribing is confined to that label. Material marketed for laboratory research is not evaluated for human use and carries no such clearance. Independent verification therefore rests on certificates of analysis, third-party testing, and documented chain of custody. The substance also appears on the World Anti-Doping Agency prohibited list within the category covering growth hormone-releasing factors.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
=== Paramount and CBS partnership === On August 11, 2025, the UFC announced a seven-year media rights agreement with Paramount Skydance Corporation worth $7.7 billion. Paramount+ will exclusively stream all events for seven years, starting in 2026. Some numbered events will also air on CBS. The agreement will allow the UFC to move away from pay-per-view as events will stream on Paramount+ at no additional cost. All 13 of the UFC's flagship events and 30 Fight Nights a year will be streamed on the Paramount+ service. UFC CEO and President Dana White announced the UFC would produce four big events per year on CBS, and that the UFC's planned card for the White House on June 14th, 2026 would be one of those events.
== See also == Bioluminescence imaging Gene expression Gene knock-in Gene regulatory network GUS reporter system Molecular cloning Promoter (genetics) Selectable marker Synthetic biology Transcription factor Transfection
The relationship between SHBG and insulin resistance has been known for some time; decades prior, ratios of SHBG and adiponectin were used before glucose to predict insulin resistance. Patients with Laron syndrome, with resultant deficient IGF, demonstrate varying degrees of alopecia and structural defects in hair follicles when examined microscopically. Because of its association with metabolic syndrome and altered glucose metabolism, anyone with early androgenic hair loss should be screened for impaired glucose tolerance and diabetes mellitus II. Measurement of subcutaneous and visceral adipose stores by MRI, demonstrated inverse association between visceral adipose tissue and testosterone/DHT, while subcutaneous adipose correlated negatively with SHBG and positively with estrogen. SHBG association with fasting blood glucose is most dependent on intrahepatic fat, which can be measured by MRI in and out of phase imaging sequences. Serum indices of hepatic function and surrogate markers for diabetes, previously used, show less correlation with SHBG by comparison. Female patients with mineralocorticoid resistance present with androgenic alopecia. IGF levels are lower in those with metabolic syndrome. Circulating serum levels of IGF-1 are increased with vertex balding, although this study did not look at mRNA expression at the follicle itself. Locally, IGF is mitogenic at the dermal papillae and promotes elongation of hair follicles. The major site of production of IGF is the liver, although local mRNA expression at hair follicles correlates with an increase in hair growth.
With Shahbaz Rana writing that the "PM had "clipped" the Finance Minister’s "decision-making wings" by depriving him of the ECC. The decision to place Aurangzeb as chairman also came after criticism from "all quarters." Pakistan newspaper Dawn, quoting a senior member of the cabinet officially stated that the PM had “regretted he would be unable to chair the ECC meetings due to his hectic schedule and engagements.” On 28 March the Cabinet Committee on Inter-Governmental Commercial Transactions (CCoIGCT) would be constituted, chaired by Khawaja Asif, with Terms of Reference (ToR) that the committee may authorize, recommend approval, and constitute a negotiation committee for a G2G or commercial agreement with a foreign state, as well as approve price-discovery mechanisms, submit recommendations for existing regulatory compliance. Operating under the clauses (c) and (d) of sub-section (2) of Section (4) of the Inter-Governmental Commercial Transactions Act, 2022.
Sources: en.wikipedia.org
The (3R, 6R, 7R) series 2, 3 showed very good levels of selectivity relative to the vasopressin receptors. However, although all the (3R, 6R, 7R) isomers of the monosubstituted aryl 2,5-DKPs with wide range of different functionality had similarly high levels of potency, they all had low bioavailability in the rat. Optimization of the pharmacokinetic (PK) profile of this template was achieved by property-based design using an estimated of human oral absorption (EHOA) which focused the SAR on 2,5-DKPs with small exocyclic aromatic rings combined with small amides. This resulted in the 2’,4’-difluoro dimethylamide 3 which achieved good oral bioavailability in the rat (53%) and dog (51%) whilst retaining good oxytocin antagonist potency (Ki= 0.63nM) and >1000 fold selectivity relative to the human vasopressin V1A, V2, V1B receptors. The introduction of polar heterocycles to improve the solubility and human cytochrome P450 (Cyp450) enzyme profile of 3 using intrinsic clearance in microsomes to drive the improvements in the later’s pharmacokinetic profile lead to the 2’,6’-dimethyl-3’-pyridyl morpholine amide Epelsiban.
The scientific name Asteroidea was given to starfish by the French zoologist de Blainville in 1830. It is derived from the Greek aster, ἀστήρ (a star) and the Greek eidos, εἶδος (form, likeness, appearance). Starfish are included in the subphylum Asterozoa along with brittle and basket stars (order Ophiuroidea), the characteristics of which include a star-shaped body as adults, with multiple arms surrounding central disc. The arms of asteroids are skeletally connected to the disc by ossicles in the body wall while ophiuroids have clearly demarcated arms. The starfish are a large and diverse class with over 1,900 living species. There are seven extant orders: Brisingida, Forcipulatida, Notomyotida, Paxillosida, Spinulosida, Valvatida and Velatida. Living asteroids, the Neoasteroidea, are distinct from their forerunners in the Paleozoic. Their classification has changed little but there is debate in regards to Paxillosida. The deep-water sea daisies, though clearly Asteroidea and currently included in Velatida, do not fit easily in any accepted lineage. Phylogenetic data suggests that they may be a sister group, the Concentricycloidea, to the Neoasteroidea, or that the Velatida themselves may be a sister group.
Lemna Ecotox testing Duckweed growth inhibition tests and standardisation OECD Guideline for Lemna Test Archived 2016-01-07 at the Wayback Machine USDA Plants Profile: North American Species Jepson Manual Treatment: Lemna
Sources: en.wikipedia.org
Not all selenoproteins were retained, however: the selenoprotein U contains selenocystine in fishes and chicken, but mammals (including humans) have a selenium-free version of this protein, replacing the selenocystine with cysteine (human genes PRXL2A, PRXL2B, PRXL2C). Another example is the human GPX5 and rodent GPX6, both of which have a vestigial SECIS element pointing clearly to a selenocystine past.
== Adverse effects == Data from phase II and III clinical trials did not detect any severe adverse effects to setipiprant. The authors were unable to identify any pattern of adverse effects that differ from placebo, including subjective reporting of symptoms and objective laboratory monitoring.
== Exocrine cell type == Morphology is what identifies ductal cells. However, there is barely anything to differentiate pancreatic ductal cells from other bodily ductal cells. There is still a lot unknown about these ductal cells. Their molecular identity still needs to be improved; more knowledge is necessary regarding stage-specific markers and the regulators of ductal cell development. It recently was discovered that the ducts start as separate microlumens in a stratified epithelium that expand, attach, and resolve to form the pancreatic ducts. These cells work with intercalating ducts that link to distinct acini and are within the larger ducts in the two core pancreatic ducts (dorsal and ventral duct) that drain into the intestine. Ductal cells are exocrine, but they are more like endocrine cells when developing. A recent lineage analysis showed that ductal cells came directly from bipotent precursor cells and have the possibility of creating either ductal or endocrine cells. Meanwhile, mature ducts have a restricted ability to transdifferentiate to other types of cells, even when the pancreas is injured.
=== Filming === Filming began in March 2019 with Glen Winter directing the pilot. Christopher Manley and Scott Peck were directors of photography on the series. Filming occurred throughout the Atlanta metropolitan area, including: Marietta, Virginia–Highland, Duluth, Lithia Springs, Dallas, Marietta Square, West End, Westlake High School, the Atlanta Center for Medical Research, Campbell Middle School, Paulding County, Smyrna, Arbor Place Mall, Vinings, Mableton, and Douglas County High School. Walter Garcia served as the series' stunt coordinator and second-unit director. He was hired to help Stargirl's staff "have a personality and be alive when she fights with it". The series continued to film in Atlanta for the second season, with filming beginning by October 28, 2020.
Sources: en.wikipedia.org
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.
It does not act directly on adipose tissue as a primary mechanism. Instead, it increases endogenous growth hormone, which then influences lipolysis and fat distribution. The reduction in visceral fat is an indirect pharmacodynamic effect.
Tesamorelin acts upstream at the pituitary to amplify natural pulsatile growth hormone release. Growth hormone injections provide exogenous hormone and bypass pituitary regulation. The two approaches therefore differ in feedback control and hormonal dynamics.
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.